BioCentury
ARTICLE | Financial News

Argos raises $42.5M in series E

August 27, 2013 12:07 AM UTC

Argos Therapeutics Inc. (Durham, N.C.) raised $42.5 million in a series E round led by new investor Pharmstandard International S.A., a holding company of Pharmstandard OJSC (RTS:PHST; LSE:PHST). New investor Green Cross Corp. (KSE:006280) also participated along with existing investors Forbion Capital Partners; TVM Capital; Lumira Capital; Intersouth Partners; Caisse de depot et placement du Quebec; Morningside Group; and Aurora Funds. Pharmstandard's Andrei Petrov will join Argos' board.

Argos' AGS-003 is in the Phase III ADAPT trial to treat metastatic renal cell carcinoma (RCC), for which the company has an SPA from FDA. The company expects data from the trial in late 2015 or early 2016. AGS-003 is a second-generation RNA-loaded autologous dendritic cell immunotherapy. ...